{
    "clinical_study": {
        "@rank": "153109", 
        "arm_group": [
            {
                "arm_group_label": "Fingolimod (FTY720) group", 
                "arm_group_type": "Experimental", 
                "description": "Drug: Fingolimod capsules will be administered as 0.5mg/day over a course of 3 consecutive days after stroke onset."
            }, 
            {
                "arm_group_label": "Control group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients will receive usual care and drug use in hospital."
            }
        ], 
        "brief_summary": {
            "textblock": "Stroke is one of the main severe disease of public health importance. Increasing evidence\n      suggests that inflammatory mechanisms plays a significant role in stroke. So, immune targets\n      are supposed to be an effective one. The sphingosine-1-phosphate receptor regulator\n      Fingolimod(FTY720)is an effective immunology modulator which has been widely used in\n      autoimmune disease and has been testified effective on stoke animal models."
        }, 
        "brief_title": "Efficacy and Safety of FTY720 for Acute Stroke", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Stroke", 
            "Vascular Accident", 
            "Cerebral Stroke", 
            "Ischemic Cerebrovascular Accident", 
            "Stroke, Acute"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cerebral Infarction", 
                "Stroke"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will enroll 42 stroke patients who have been diagnosed with stroke and meet the\n      inclusion criteria.\n\n      After successfully meeting initial screening criteria, investigators will contact the\n      family, explain the study, and send a consent form for their review.\n\n      After that, patients will be given 0.5mg/day oral fingolimod over a course of 3 consecutive\n      days , then investigators will make a neurofunctional assessment before and 7days, 30 days\n      and 90days after oral fingolimod. And Magnetic Resonance of the brain before, 7days, 14days\n      and 90days after oral fingolimod. Furthermore 5ml intravenous blood for flow cytometry is\n      also taken before and 1day,3days,7days after fingolimod use."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18-80 years\n\n          -  Clinical presentation of spontaneous intracerebral hemorrhage/ischemic stroke\n\n          -  MRI/MRA scan compatible with spontaneous intracerebral hemorrhage/ ischemic stroke\n\n          -  Time to fty720 treatment< 72 h from symptom onset\n\n          -  Glasgow Coma Score >6 on initial presentation or improvement to a Glasgow Coma Score\n             >6 within the time frame for enrollment.\n\n          -  Primary supratentorial ICH of \u22655cc and <30cc\n\n          -  TOAST: Large-artery atherosclerosis\n\n        Exclusion Criteria:\n\n          -  Patients who will undergo surgical evacuation of intracerebral hemorrhage\n\n          -  Inability to undergo neuroimaging with Magnetic Resonance\n\n          -  Glasgow Coma Score < 6.\n\n          -  Baseline modified Rankin Scale score >1\n\n          -  Primary intraventricular hemorrhage ICH due to coagulopathy (PT > 15 s or\n             International Normalized Ratio > 1.3, Partial Thromboplastin Time > 36) or trauma\n\n          -  Thrombocytopenia: platelet count <100 000\n\n          -  Clinically significant hepatic disease as demonstrated by history, clinical exam\n             (ascites, varices), or laboratory findings (LFTs >2x normal, coagulopathy as\n             described)\n\n          -  Comorbid conditions likely to complicate therapy including but not limited to the\n             following: a history of New York Heart Association class II, III, or IV Congestive\n             Heart Failure; end-stage acquired immune deficiency syndrome\n\n          -  Pregnancy\n\n          -  Malignancy (history of or active)\n\n          -  Bradyarrhythmia and Atrioventricular Block\n\n          -  Concomitant use with antineoplastic,immunosuppressive or immune modulating therapies\n\n          -  Macular Edema"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02002390", 
            "org_study_id": "IRB2013-054-02"
        }, 
        "intervention": {
            "arm_group_label": "Fingolimod (FTY720) group", 
            "description": "A sphingosine-1-phosphate receptor regulator", 
            "intervention_name": "Fingolimod", 
            "intervention_type": "Drug", 
            "other_name": "FTY720"
        }, 
        "intervention_browse": {
            "mesh_term": "Fingolimod"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Stroke,Fingolimod(FTY 720), treatment", 
        "lastchanged_date": "April 20, 2014", 
        "location": {
            "contact": {
                "email": "fshi@tijmu.edu.cn", 
                "last_name": "Fu-Dong Shi, MD,PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Tianjin", 
                    "country": "China", 
                    "state": "Tianjin", 
                    "zip": "300052"
                }, 
                "name": "Tianjin Medical University General Hospital"
            }, 
            "investigator": {
                "last_name": "Fu-Dong Shi, MD,PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of FTY720 for the Treatment of Acute Stroke", 
        "overall_contact": {
            "email": "fshi@tijmu.edu.cn", 
            "last_name": "Fu-Dong Shi, MD,PhD"
        }, 
        "overall_official": {
            "affiliation": "Tianjin Medical University General Hospital", 
            "last_name": "Fu-Dong Shi, MD,PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Neurofunctional assessment including NIHSS, modified Barthel Index, modified Rankin Scale,and Glasgow coma scale are used to describe the clinical improvement at baseline, 7days, 14days, 30days and 90days.", 
            "measure": "Clinical improvement", 
            "safety_issue": "Yes", 
            "time_frame": "up to 90 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02002390"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Tianjin Medical University General Hospital", 
            "investigator_full_name": "Fu-Dong Shi", 
            "investigator_title": "Head of Neurology Department", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Outcomes are measured at baseline, 7 days, 14 days and 90 days after onset", 
                "measure": "Change in image", 
                "safety_issue": "Yes", 
                "time_frame": "up to 90 days"
            }, 
            {
                "description": "Use the flow cytometry to measure the change at baseline, 1 day, 3 days, 7 days after drug use", 
                "measure": "Change in immunology function", 
                "safety_issue": "Yes", 
                "time_frame": "up to 7 days"
            }
        ], 
        "source": "Tianjin Medical University General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tianjin Medical University General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}